Maynard Um
-
-
-
-
-
-
-
Denali Therapeutics Inc. (DNLI) PT Raised to $40 at Goldman Sachs
-
-
-
-
-
-
-
Denali shares clinical data on enzyme treatments for rare diseases
-
-
-
-
-
-
-
Denali Therapeutics (DNLI) Confident of 2026 Approval for tivi/DNL310 - Stifel
-
-
-
-
-
-
-
FDA extends review timeline for Denali's Hunter syndrome treatment
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Denali Therapeutics Inc. (DNLI)
-
-
-
-
-
-
-
Morgan Stanley Starts Denali Therapeutics Inc. (DNLI) at Overweight
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
-
401,642 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

